Overview

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Status:
Completed
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Avelas Biosciences, Inc.
Collaborators:
Clinipace Worldwide
RRD International, Inc.